SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 /PRNewswire/ -- Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced ...
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene therapy targeting Pitt Hopkins syndrome. The multicentre, open-label, global ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The 10-employee company ...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 /PRNewswire/ -- Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results